The deal couples Novo Nordisk’s experience in diabetes with Dewpoint’s discovery and artificial intelligence platform. The companies will work to discover potential molecule drugs against multiple condensate targets.
The company announced price cuts to Lantus, its most-prescribed insulin product, after similar moves by rivals Novo Nordisk and Eli Lilly and Co.
After Eli Lilly announced it would take measures to cap insulin prices, Novo Nordisk will reportedly follow suit. There may be strategic reasoning behind these moves.
Novo will reduce the list price of its NovoLog insulin by 75%, and for Novolin and Levemir by 65%.
The buyout will give Sanofi rights over Tzield (teplizumab-mzwv), Provention’s diabetes delay drug, which is the first-ever disease-modifying treatment to delay disease progression.
Genome editing has been a hot-button topic in recent years. With the rise of CRISPR technology in the news, this is not surprising for either scientists or investors.
Presently, Medicare is forbidden by law from paying for antiobesity prescriptions. But should the bipartisan The Treat and Reduce Obesity Act get reintroduced and passed by Congress, Medicare will be compelled to cover drugs for weight loss.
The company’s highly anticipated weight loss medicine, Wegovy, will soon be made available to thousands of people in the UK.
Medtronic Plc said on Tuesday it expects inflation in various markets to hit its profit in the next fiscal year after the medical device maker beat earnings estimate for the third quarter on strong demand for its heart and diabetes devices.
The company plans to expand its manufacturing capacity at the Research Triangle Park facility in North Carolina to support increased demand for its key diabetes drugs. It has been struggling to meet high demand for the drugs Trulicity and Mounjaro, especially due to production of multiple dosage forms for each of them.